CD14 and myelodysplastic syndrome: Another recurrent aberrancy observed in LR-MDS patients consisted in a marked decrease in the fraction of CD14+CD16+ monocytes, comparatively to controls (median values of 3% and 12%, ranging from 0 to 8% and from 4 to 28%, in patients and in controls, respectively; p < 0.001) (Fig. 5 and Table 5).